Argobio launches with 50 million euros, aiming to create pioneering biotech spinouts

3 March 2021

Argobio, a newly-created start-up studio dedicated to life sciences, today announced its launch with 50 million euros ($60.3 million) of committed capital.

Argobio was initiated by Kurma Partners, a Paris and Munich-based healthcare venture capital firm, and Bpifrance, the French national investment bank.

Complementary strategic investors were Italy’s privately-owned drugmaker Angelini Pharma, which gains a 30% with a loan of 15 million euros, Evotec (EVT: Xetra), a Germany-based drug discovery alliance and development partnership company, and France’s Institut Pasteur, internationally renowned center for biomedical research.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK